Analysts have raised their price target for Granules India from ₹573.71 to ₹604.29. They cited improved profitability forecasts, even though revenue growth expectations are slightly lower.
What's in the News
- Granules India will hold a Board Meeting on November 13, 2025 to consider and approve the unaudited financial results for the second quarter and half-year ended September 30, 2025 (Key Developments).
- The company has received an Establishment Inspection Report from the U.S. FDA for its API Unit-I facility at Bonthapally, Hyderabad. The inspection was classified as Voluntary Action Indicated, with one observation that the company addressed within the required timeframe (Key Developments).
- The inspected facility is recognized as one of the world's largest single-site Paracetamol API manufacturing plants by volume. Granules India also produces Metformin and Guaifenesin APIs at this unit (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has increased from ₹573.71 to ₹604.29.
- Discount Rate has risen marginally from 12.73% to 12.76%.
- Revenue Growth forecast has declined from 15.53% to 13.88%.
- Net Profit Margin expectation has improved from 12.67% to 13.58%.
- Future P/E multiple has decreased from 22.66x to 21.63x.
Have other thoughts on Granules India?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.